| | Compound | Description | Phase | Tumor |
| | MK-2206 | Allosteric kinase inhibitor | I | Metastatic solid tumors, non-small-cell lung cancer, advanced solid tumors, breast cancer, leukemia, lymphoma, neoplasms malignant, kidney cancer, prostate cancer, brain and central nervous system tumors, small intestine cancer | | II | Ovarian cancer, fallopian tube and primary peritoneal cancer, leukemia, lymphoma, colorectal neoplasms, breast cancer, esophageal cancer, gastric cancer, endometrial cancer, prostate cancer, recurrent nasopharyngeal carcinoma, head and neck cancer, kidney cancer, lung cancer, extrahepatic bile duct cancer, gallbladder cancer, liver cancer |
| | Perifosine | Lipid-based allosteric kinase inhibitor | I | Pediatric solid tumors, multiple myeloma, solid tumors, colon cancer, renal cancer, ovarian cancer, neoplasms, brain and central nervous system tumors, leukemia, lymphoma | | II | Malignant gliomas, CNS, brain cancer, Waldenstrom's macroglobulinemia, lymphomas, colon cancer, gastrointestinal stromal tumors, multiple myeloma, chondrosarcomas, alveolar soft part sarcomas, kidney cancer, renal cell carcinoma, leukemia, lymphoma, brain and central nervous system tumors, melanoma (skin), endometrial cancer, sarcoma, prostate cancer, head and neck cancer, pancreatic cancer, breast cancer | | | III | Multiple myeloma, colorectal cancer |
| | GSK-2141795 | ATP competitive inhibitor | I | Ovarian cancer, solid tumors, and lymphoma |
| | GSK-2110183 | ATP competitive inhibitor | I | Multiple myeloma, hematologic malignancies | | II | Langerhans cell histiocytosis, hematologic malignancies |
| | RX-0201 | interfering RNA | II | Metastatic pancreatic cancer |
|
|
